Tutorials
Seagen Inc logo

Seagen Inc

$ 175.81 -0.05 (-0.03%) 10:08 PM EST
On watch
P/E:
At Loss
P/B:
11.05
Market Cap:
$ 32.43B
Enterprise V:
$ 30.63B
Volume:
706.41K
Avg Vol (2M):
1.44M
Also Trade In:
Volume:
706.41K
Market Cap $:
32.43B
PE Ratio:
At Loss
Avg Vol (2-Month):
1.44M
Enterprise Value $:
30.63B
PB Ratio:
11.05
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Seagen Inc
NAICS : 325414 SIC : 2836
21823 - 30th Drive South East, Building 3, Bothell, WA, USA, 98021
Description
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Name Current Vs Industry Vs History
Cash-To-Debt 36.86
Equity-to-Asset 0.81
Debt-to-Equity 0.02
Debt-to-EBITDA -0.08
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 27.73
Distress
Grey
Safe
Beneish M-Score -2.58
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 49.02
9-Day RSI 51.63
14-Day RSI 54.68
6-1 Month Momentum % 28.16
12-1 Month Momentum % 8.98

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.57
Quick Ratio 4.04
Cash Ratio 3.04
Days Inventory 229.28
Days Sales Outstanding 81.92
Days Payable 109.24

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.6

Financials (Next Earnings Date:2022-10-28 Est.)

SGEN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:SGEN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1,777.873
EPS (TTM) ($) -4.03
Beta 0.17
Volatility % 40.49
14-Day RSI 54.68
14-Day ATR ($) 5.136607
20-Day SMA ($) 175.538
12-1 Month Momentum % 8.98
52-Week Range ($) 105.43 - 192.7867
Shares Outstanding (Mil) 184.44

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Seagen Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More